
Astorg acquires surgery supplies manufacturer Demetra
Astorg has invested in Demetra, an Italian manufacturer of surgical devices, while minority backer Keensight has exited the business.
French buyout house Keensight merged medical technology businesses Tecres and Aap Biomaterials into Demetra Holding in 2016. Prior to the transaction, Keensight fully bought Aap Biomaterials from parent company Aap Implantate for EUR 36.6m, according to press reports at the time. Keensight then invested an undisclosed amount in the newco, Demetra Holding, alongside Tecres's shareholders, with the latter retaining a controlling stake in the group.
Keensight said that the company tripled revenues during its ownership. It also expanded internationally, especially in the US and in Asia, where Demetra signed new joint ventures and opened new production sites.
Astorg is currently deploying equity via the latest vehicle in its flagship strategy, Astorg VII, which held a final close in January 2019 on EUR 4bn. The fund targets B2B businesses with enterprise values of more than EUR 200m and deploys equity tickets of EUR 100m-400m.
Astorg has had a busy 2021 on the buy-side so far. It recently teamed up with Bridgepoint to buy Irish financial software company Fenergo from Insight Partners. According to the Irish Times, Bridgepoint and Astorg jointly acquired a majority stake for USD 600m in a deal valuing the business at USD 1.165bn.
Astorg also bought French food ingredients producer Solina from Ardian; according to local publication L'Agefi, the deal valued the company at around EUR 1.7bn.
The GP is preparing the launch of its next flagship fund, as reported. It is also fundraising for its Mid-Cap Fund, with the process expected to be finalised this summer.
Company
Created in 2016 following the combination of Italy-based Tecres and Germany-based Osartis, Demetra develops, manufactures and distributes products used in orthopaedic implant surgeries and spine interventions. It employs 200 staff.
The group notably develops bone cement, a product used for the fixation of orthopaedic implants and for the filling of vertebral compression fractures. It also offers preformed spacers, which are ready-to-use, antibiotic-loaded temporary implants used to treat local infections that can occur for patients who have had implant surgery.
The two businesses continue to operate under their respective brands.
People
Astorg – Lorenzo Zamboni (partner).
Keensight - Pierre Rémy (managing partner).
Advisers
Vendors – Rothschild & Co (M&A); Gattai Minoli Partners (legal).
Equity – BonelliErede (legal); EY (financial due diligence).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater